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Abstract : Study Objectives : Although the full-night continuous positive airway pressure (CPAP) titration (fnPT) 
has been recognized as the gold standard for determining an optimal therapeutic pressure for obstructive sleep 
apnea (OSA) treatment, it is labor-intensive, time-consuming because it requires overnight polysomnography 
attended by well-experienced sleep technologists. The aim of this study is to develop a practical and feasible al-
ternative titration method. Methods : We assessed demographic data and diagnostic polysomnographic parame-
ters, time spent in CPAP titration, CPAP efficacy and long-term adherence of the two groups of our OSA patients 
who had received CPAP titration either by fnPT (n = 46) or by afternoon CPAP titration (aPT, n = 22). Main re-
sults : Mean total recording time of aPT was significantly shorter than that by fnPT (p < 0.0001). There was no sig-
nificant difference in mean residual apnea hypopnea index (AHI) on treatment, percent days with device usage, 
cumulative device usage hours during the 360 days, average device usage hours per day (360 days, days used), 
and percent of days with device usage ≥ 4 hours during the 360 days after starting CPAP treatment between the 
two groups. Conclusions : Our study demonstrated that aPT was feasible procedure as an alternative to fnPT. J. 
Med. Invest. 68 : 170-174, February, 2021
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INTRODUCTION
 
Obstructive sleep apnea (OSA) is characterized by repetitive 
collapse of the upper airway during sleep, leading to recurrent 
arousals, intermittent hypoxia and hypercapnia and numerous 
surges of sympathetic activity (1, 2). It has been widely recog-
nized that OSA is associated with neuropsychological dysfunc-
tion (3), decreased quality of life (4) and motor vehicle accidents 
(5). In addition, increased risk of hypertension (6), metabolic 
syndrome (7) and higher risk of cardiovascular diseases (8) have 
been well documented. In respect of the prevalence, OSA is high 
in the general adult population, ranging from 9 to 38% (9), which 
means that OSA is the one of the biggest public health problems.
As countermeasures, continuous positive airway pressure 
(CPAP) has been considered the first line treatment for OSA. 
CPAP improves quality of life (10), reduces motor vehicle ac-
cidents (11), decreases the risk of hypertension (12), metabolic 
syndrome (13) and cardiovascular diseases (14). Despite these 
highly significant treatment effects, CPAP adherence remains a 
major obstacle to its effectiveness (15). Although CPAP regular 
use is defined as at least 4 hours use on 70% of days (16), CPAP 
adherence remains highly variable (17-20). In the recent large 
randomized clinical trials (21), CPAP effects on hypertension 
and cardiovascular events were not significant, but the subgroup 
analysis of patients with OSA using CPAP for more than 4 hours 
per night demonstrated the significant treatment effects (22). 
This result alerted us to keep in mind that higher CPAP adher-
ence is essential for OSA treatment.
In this respect, various factors that could influence CPAP 
adherence have been studied in the western countries. The most 
recent comprehensive review by Mehrtash and his colleagues, 
summarized these factors from four different domains : socio-de-
mographic characteristics, disease severity, psychosocial factors, 
and side-effects (23). In addition, it has been widely known that 
there is an optimal pressure of CPAP to stabilize the opening 
of the upper airway, which differs from one patient to another, 
so CPAP titration played an important role in increasing CPAP 
adherence (24). Consequently, American Academy of Sleep Med-
icine (AASM) established the clinical guideline (25) regulating 
that the standard way of CPAP titration should be conducted by 
the full-night CPAP titration (fnPT). The main aim of fnPT is to 
determine an optimal therapeutic pressure that abolishes respi-
ratory events during sleep of OSA patients by using polysomnog-
raphy (PSG) and a CPAP device at the same time. The drawback 
of fnPT is that this procedure requires overnight PSG at a sleep 
lab attended by well-experienced sleep technologists, resulting 
in high cost from the viewpoint of time and labor. Therefore, we 
need a practical alternative way of titration which is feasible in 
Japan where sleep medicine is still underdeveloped.
The aim of this study is to develop a practical and feasible 




This is the retrospective study dealing with consecutive 122 
OSA patients who underwent CPAP titration from April 2013 to 
March 2018 in our sleep laboratory (Figure 1). Our sleep center 
specialized in all kinds of sleep-related disorders, and it was our 
daily clinical routine to get demographic data such as gender, 
age, height, weight, and working status as well as Epworth 
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sleepiness scale (ESS) at the first visits of new patients. When 
it was clinically indicated, attended all-night PSG for diagnosis 
was routinely performed. All the PSG data were scored accord-
ing to AASM criteria (26). OSA was defined when apnea hypo-
pnea index (AHI) was five or more on diagnostic PSG.
This study was approved by the Institutional Review Board 
of Kansai Electric Power Medical Research Institute. The study 
was conducted in according to the principles of the Declaration 
of Helsinki. 
CPAP education
All the 122 patients received CPAP education lasting about 
30 minutes as clinical routine of our sleep lab on the same day 
of the titration. This educational session was carried out by 
experienced sleep technologists before starting CPAP titration. 
The session was composed of explaining reasons for CPAP use, 
its clinical benefit, mask fitting including patients trialing ones 
of different styles, training of how to put on and take off a mask, 
hands-on demonstration of CPAP devices, and acclimatization 
to CPAP.
CPAP titration 
FnPT was carried out by well-experienced sleep technologists 
using the AASM guidelines (25). As for fnPT, the optimal pres-
sure setting procedure was based on the AASM algorithm (25). 
We invented aPT that was performed in the early afternoon 
starting around 2 p.m. and ending before 4 p.m. by using PSG 
when the patients was encouraged to take a nap. The procedure 
to find out an optimal pressure was mostly equivalent to fnPT 
except that fnPT required the occurrence of REM sleep on su-
pine with no respiratory events or arousals. In addition, if the 
patients did not achieve REM sleep during aPT, the study was 
ended. We calculated the number of patients who achieved REM 
sleep during both aPT and fnPT.
Of the 122 patients, 72 patients underwent fnPT and 50 pa-
tients received aPT (Figure 1). The total recording time of fnPT 
and aPT was calculated after titration. Due to retrospective 
nature of this study, our patients were not randomly allocated 
to aPT or fnPT.
CPAP prescription
After the titration, sleep specialists reviewed the titration data. 
As auto-titrating CPAP devices are available to all the patients under 
the Japanese national medical insurance system, an optimal pres-
sure range (for example, 4-7 cmH2O) was prescribed except one 
patient who opted out to fixed-pressure. 117 out of 122 patients 
were given either REMStar (Philips Respironics, Murrysville, 
PA, USA) or DraemStation (Philips Respironics, Murrysville, 
PA, USA) and used the same machine throughout the study. As 
this is the retrospective study, these two types CPAP machines 
were not randomly allocated, however, the algorithm of these 
two machines from a single manufacturer, Philips Respironics, 
was basically identical. Five remaining patients who opted out to 
another CPAP machines from other manufactures than Philips 
Respironics were excluded at this point (Figure 1).
CPAP follow-up system
Regular CPAP follow-up at the clinic was mandatory accord-
ing to the Japanese national medical insurance system. Patients 
were not allowed to purchase CPAP devices directly from the 
providers in Japan, but the public insurance completely covered 
the rental fee of CPAP devices on the condition that the patients 
come to the clinic at least once per three months. On their reg-
ular visits, the patients got CPAP adherence data downloaded 
by sleep technologists in addition to consultation by sleep spe-
cialists. Troubleshooting about CPAP devices or interfaces was 
sorted out by sleep technologists.
During the one year follow-up, the 49 patients were excluded 
for the following reasons : Patients who were unable to continue 
to use CPAP for more than one year (fnPT : 9, aPT : 21), patients 
who moved to another hospitals or sleep clinics (fnPT : 12, 
aPT : 6). One patient who underwent fnPT was excluded because 
his first one month data was missing due to technical error. As a 
results, the subjects for analysis were 46 patients after fnPT and 
22 patients after aPT (Figure 1). As for the patients who were not 
able to continue to use CPAP for more than one year, we calculat-
ed CPAP dropout rate within one year.
CPAP efficacy
The CPAP device had capacity to record the nightly amount 
of the usage and to measure the airflow of users’ breathing, en-
abling us to obtain the residual numbers of apnea and hypopne-
as. By downloading the data, mean residual AHI was available. 
As the CPAP device was unable to measure sleep time, the mean 
residual AHI was calculated by dividing the number of apneas 
and hypopneas by operating hours, however, this mean residual 
AHI has been widely used as CPAP efficacy.
CPAP adherence
We collected the data via a memory card at 360 days after the 
introduction of CPAP. This assessment included percent days 
with device usage during the 360 days, cumulative device usage 
Figure 1.　Design of the study.
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hours during the 360 days, average device usage hours per day 
during the 360 days, average device usage hours per day during 
the days of device used of this period, and percent of days with 
the device usage hours ≥ 4 hours during the 360 days.
Statistical analysis
Statistical analysis was done using JMP PRO 14.0.0 (SAS 
Institute Technology, U.S.). All demographic, polysomnographic 
variables, sleep parameters and CPAP adherence data were de-
scribed using mean and standard deviation. A chi-square analy-
sis with Fisher’s exact test was performed to compare categorical 
data. The p values < 0.05 were assessed to represent statistical 
significance.
RESULTS
Demographic and diagnostic polysomnographic data
Demographic characteristics of the two groups did not show 
significant difference (Table 1). As for CPAP dropout rates, 
group of aPT (42.0%) was significantly higher than that of fnPT 
(12.5%). Most of polysomnographic parameters at the diagnosis, 
such as total sleep time, sleep efficiency, sleep latency, AHI, 
the number of 3% desaturations per one hour sleep (oxygen 
desaturation index by 3%, ODI3%), lowest oxygen saturation 
(lowest SpO2), and arousal index were not significantly different 
between two groups (Table 2).
There was one parameter that showed significant difference, 
which was percentage of total sleep time with oxygen saturation 
below 90% (% time SpO2 < 90%). This percentage was signifi-
cantly higher in aPT than in fnPT group (17.3 ± 18.9 vs 7.4 ± 9.1, 
p < 0.03).
REM sleep occurrence and time spent on CPAP titration
8 out of 22 patients (36.4%) achieved REM sleep during aPT, 
while all of the 46 patients (100%) during fnPT (p < 0.0001). 
Mean total recording time was significantly shorter in aPT group 
than in fnPT group (73.0 ± 13.9 vs 501.5 ± 41.1 min, p < 0.0001). 
CPAP efficacy and adherence
There was no significant difference in mean residual AHI 
during the 360 days (fnPT vs. aPT, 3.6 ± 2.5 vs. 3.1 ± 1.2), per-
cent days with device usage during the 360 days (82.5 ± 16.7 
vs. 85.4 ± 17.7%), cumulative device usage hours during the 360 
days (1621.2 ± 510.1 vs. 1727.1 ±  619.3 hours), average device 
usage hours per day during the 360 days (4.5 ± 1.4 vs. 4.8 ± 1.7 
hours), average device usage hours per day during the days 
of device used of this period (5.4 ± 1.0 vs. 5.5 ± 1.4 hours), and 
percent of days with device usage hours ≥ 4 hours (66.0 ± 21.8 vs. 




This study showed that aPT, a new modified method of CPAP 
titration, was as effective as fnPT in that there was no signif-
icant difference in the mean residual AHI (less than five) on 
CPAP and in adherence (more than 70% days of device usage 
and more than four hours usage per day) during the 360 days 
follow-up. In addition, the average hours of recording time of aPT 
was significantly shorter than that of fnPT. Compared to fnPT, 
aPT has an advantage in that it took only one and a half hours.
Another advantage of our procedure was chronobiologically 
appropriate time slot when aPT was performed. In contrast to 
our method, the previous two studies (27, 28) did the titration in 
the morning, and the one did not describe the time zone of their 
titration (29). Regarding the chronobiological change in the vig-
ilance level, Lavie and Segal (30) demonstrated that sleep pro-
pensity was second highest in the early afternoon (i.e. 2-4 p.m.) 
by using ultrashort 7-min sleep/ 13-min wake cycle schedule for 
Table 1.　Demographic data of our participants.
fnPT aPT p value
Number 46 22 -
M / F 43 / 3 21 / 1 1.*
Age (years) 58.3 ± 12.8 58.9 ± 12.3 .753
Height (cm) 168.9 ± 7.0 168.6 ± 6.1 .613
Weight (kg) 77.1 ± 14.5 77.7 ± 17.8 .733
BMI (kg / m2) 26.9 ± 4.2 27.1 ± 4.9 .906
Working status
(Full-time / Part-time / Retire /
Homemaker)
(36 / 1 / 9 / 0) (16 / 2 / 3 / 1) .220*
ESS 10.1 ± 5.4 10.4 ± 4.3 .457
Data presented n or as mean ± standard deviation. BMI, body 
mass index ; ESS, Epworth sleepiness scale. *Fisher’s exact test
Table 2.　Diagnostic polysomnographic parameters in the two groups.
fnPT (n = 46) aPT (n = 22) p value
TST (min) 376.5 ± 71.5 392.7 ± 75.2 .362
Sleep efficiency (%) 82.1 ± 11.3 83.0 ± 12.0 .684
Sleep latency (min) 22.0 ± 20.4 16.1 ± 19.3 .067
AHI 38.7 ± 15.8 43.3 ± 18.3 .268
ODI3% 34.6 ± 16.8 40.0 ± 18.7 .211
Lowest SpO2 (%) 77 ± 8 73 ± 13 .325
% time SpO2 < 90% (%) 7.4 ± 9.1 17.3 ± 18.9 .028#
Arousal index 34.2 ± 13.1 38.5 ± 16.7 .274
Data presented as mean ± standard deviation. TST, total sleep 
time ; AHI, apnea hypopnea index ; ODI3%, the number of 3% 
desaturations per one hour sleep ; % time SpO2<90%, percentage 
of total sleep time with oxygen saturation below 90%. #statistical 
significance.
Table 3.　Efficacy and adherence during 360 days after CPAP titration.
fnPT (n = 46) aPT (n = 22) p value
Mean residual AHI* 3.6 ± 2.5 3.1 ± 1.2 .718
Percent days with device 
usage (%) 82.5 ± 16.7 85.4 ± 17.7 .277
Cumulative device usage 
hours during the 360 days 1621.2 ± 510.1 1727.1 ± 619.3 .471
Average device usage hours 
per day during the 360 days 4.5 ± 1.4 4.8 ± 1.7 .471
Average device usage hours 
per day during the days of 
device used of this period
5.4 ± 1.0 5.5 ± 1.4 .866
Percent of days with usage 
≥ 4 hours (%) 66.0 ± 21.8 68.0 ± 24.4 .901
Data presented as mean ± standard deviation. *Mean residual 
AHI was calculated by dividing the number of apnea hypopnea by 
operating hours. 
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48 hours. In this context, there is a major benefit about aPT since 
the patients have the titration during the time slot when they 
were physiologically sleepy.
It has been widely recognized that the mean residual AHI 
counted by the CPAP device was a good parameter indicating 
decrease in respiratory events. Therefore we compared the mean 
residual AHI of the both groups monitored by the CPAP device 
during 360 day follow-up. The mean residual AHI in two groups 
was less than five during the 360 days, which means aPT was ef-
fective as fnPT. Unfortunately we could not compare this efficacy 
to the previous studies (27-29), as they were performed before the 
era when CPAP devices did not have the function of monitoring 
respiratory events.
It is unarguable that one of the most important aspects of 
CPAP treatment is to maintain adherence on a long-term basis. 
In general CPAP use of 4 hours / night on 70% of nights has been 
accepted as a clinical and empiric benchmark of CPAP adher-
ence (16). In fact, there are two factors that define the CPAP 
adherence : one is frequency of CPAP use and the other is the 
duration of follow-up. When evaluating the CPAP adherence 
in respect of these two aspects, our patients initiating CPAP 
treatment after aPT fulfilled the adherence requirement as good 
as the patients who underwent fnPT. Both of the groups showed 
over 80% days with device usage and averagely 4.5 hours usage 
per day (360 days), and averagely 5.4 hours usage per day (days 
used) during the 360 days after starting CPAP.
There are several limitations of this study. Firstly, patients 
were not randomly assigned to aPT or fnPT group due to the 
retrospective nature. Secondary, in the aPT, 8 out of 22 patients 
(36.4%) achieved REM sleep while all of the 46 patients in the 
fnPT group achieved REM sleep. As AASM criteria recom-
mends that an optimal titration should include supine REM 
sleep (25), the aPT could not be completely comparable to the 
fnPT. This might partially explain the higher dropout rates of 
the aPT group. Thirdly, it still remains unknown how to choose 
the appropriate patients who are most likely to be adherent to 
CPAP treatment after aPT. Thus, further prospective randomly 
allocated studies would be needed.
In conclusion, aPT has an advantage in that it took only one 
and half hours to be completed at the time zone when people are 
physiologically sleepy. Most importantly, the optimal pressure 
setting determined by aPT was as effective as that by fnPT and 
there was no difference in long-term adherence between the two 
groups. Thus, aPT could be a practical alternative way of titra-
tion with low cost and labor.
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